Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Iberogast on heartburn in dyspepsia
2016-003739-40Phase 3Completed
- Sponsor
- AMC Health
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Iberogast in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD), sponsored by AMC Health. Primary endpoint: Gastro-oesophageal reflux disease symptom score improvement. Started Mar 2017; status: completed.
02
Drugs
Iberogast
03
Conditions
functional dyspepsia (FD)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2016-003739-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003739-40.